Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

C3L-00923

— · cohortSQ1

1c4a7bd6-4b1c-53e9-9e0b-4e0004953682

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSQ1
subtype
cohortSQ1
age_years
71.16769336

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.350
  • INTERFERON_ALPHA_RESPONSE+0.310
  • INTERFERON_GAMMA_RESPONSE+0.290
  • OXIDATIVE_PHOSPHORYLATION+0.290
  • IL6_JAK_STAT3_SIGNALING+0.180
  • ANDROGEN_RESPONSE+0.120
  • KRAS_SIGNALING_UP+0.120
  • BILE_ACID_METABOLISM+0.110
  • E2F_TARGETS+0.110
  • INFLAMMATORY_RESPONSE+0.110

Top 10 suppressed

  • PANCREAS_BETA_CELLS-0.380
  • ANGIOGENESIS-0.370
  • MYC_TARGETS_V2-0.350
  • GLYCOLYSIS-0.280
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
  • HYPOXIA-0.270
  • CHOLESTEROL_HOMEOSTASIS-0.260
  • NOTCH_SIGNALING-0.250
  • APICAL_JUNCTION-0.240
  • COAGULATION-0.240

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1aMVAC.P_006_TURBT_S224
bladder-landscape@3
——0.837
2SRR6013594
lung-landscapes@6
—cohortMD20.769
3MBCProject_1542_T2_RNA
breast-umap@18
—D0.758
4SRR25043622
head-neck@1
——0.750
5SRR33532827
breast-umap@18
—D0.746
6SRR6013555
lung-landscapes@6
—cohortMD20.741
7OCIAML2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
ccle-aml@v2024.1
AML—0.731
8MNG628
mng-umap@100
——0.718
9ULC0563T_S23
lung-landscapes@6
—cohortMD20.716
10KASUMI6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
ccle-aml@v2024.1
AML—0.714

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.350Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.310Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.290Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.290Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.180Inavolisib— uncovered
ANDROGEN_RESPONSE0.120Inavolisib— uncovered
KRAS_SIGNALING_UP0.120Inavolisib— uncovered
BILE_ACID_METABOLISM0.110Inavolisib— uncovered
E2F_TARGETS0.110Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.110Idelalisib— uncovered
MYC_TARGETS_V10.090Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.090Inavolisib— uncovered
COMPLEMENT0.060Inavolisib— uncovered
DNA_REPAIR0.060Idelalisib— uncovered
IL2_STAT5_SIGNALING0.060Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.050Inavolisib— uncovered
SPERMATOGENESIS0.050Inavolisib— uncovered
PEROXISOME0.040Idelalisib— uncovered
G2M_CHECKPOINT0.010Inavolisib— uncovered
KRAS_SIGNALING_DN0.010Remibrutinib— uncovered